Nov 18 (Reuters) - Arrowhead Pharmaceuticals Inc
:
* ARROWHEAD PHARMACEUTICALS PRESENTS NEW DATA AT AHA24 FROM PALISADE PHASE 3 STUDY AND OPEN-LABEL EXTENSION FROM MUIR AND SHASTA-2 STUDIES OF PLOZASIRAN
* ARROWHEAD PHARMACEUTICALS: MEAN REDUCTIONS IN TRIGLYCERIDES OF UP TO -73% IN PATIENTS FROM MUIR AND -86% IN PATIENTS FROM SHASTA-2 IN STUDY
* ARROWHEAD PHARMACEUTICALS: PLOZASIRAN INDUCED DEEP AND SUSTAINED REDUCTIONS IN TRIGLYCERIDES
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。